Jove
Visualize
Contact Us

Related Experiment Videos

Treatment. Disease-modifying therapies.

J D Lieberman1, S Schatten

  • 1Department of Medicine, Emory University School of Medicine, Atlanta, Georgia.

Rheumatic Diseases Clinics of North America
|April 1, 1988
PubMed
Summary

Many systemic lupus erythematosus patients benefit from antimalarials and NSAIDs, avoiding long-term corticosteroids. Early intervention with immunosuppressants is crucial for severe cases to prevent organ damage.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vicarious annihilation: the effect of mortality salience on perceptions of hate crimes.

Law and human behavior·2002
Same author

The lure of unconventional therapy for rheumatic disease: how powerful is it?

JAAPA : official journal of the American Academy of Physician Assistants·2000
Same author

Terror management and aggression: evidence that mortality salience motivates aggression against worldview-threatening others.

Journal of personality and social psychology·1998
Same author

Autoimmune progesterone dermatitis: onset in a women without previous exogenous progesterone exposure.

Southern medical journal·1997
Same author

Methotrexate in systemic lupus erythematosus.

The Journal of rheumatology·1997
Same author

Intravenous immunoglobulin therapy in systemic lupus erythematosus-associated thrombocytopenia.

Arthritis and rheumatism·1990
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Background:

  • Systemic lupus erythematosus (SLE) management varies significantly among patients.
  • Corticosteroids are effective but associated with severe toxicities, especially with prolonged high-dose use.
  • Identifying patients at risk for severe disease is critical for early, tailored treatment.

Purpose of the Study:

  • To review current treatment strategies for SLE.
  • To highlight the need for early intervention in severe SLE cases.
  • To explore future predictive markers for disease severity.

Main Methods:

  • Review of existing literature on SLE treatment modalities.
  • Discussion of the risks and benefits of corticosteroids versus immunosuppressive therapies.
  • Exploration of potential future diagnostic tools like HLA haplotypes and T-cell subsets.

Main Results:

  • Antimalarials and NSAIDs are effective for many SLE patients, minimizing corticosteroid exposure.
  • Immunosuppressive drugs and plasmapheresis are indicated for severe or refractory SLE to prevent organ damage.
  • Predictive markers like HLA haplotypes and T-cell subsets may aid in early identification of severe disease.

Conclusions:

  • A personalized approach to SLE treatment is essential.
  • Early identification of severe disease can guide the use of potent immunosuppressive therapies.
  • Future research into predictive markers and treatment mechanisms will enable more rational SLE management.

Related Experiment Videos